# Food supplements in the treatment of male infertility: a critical review on their formulations and use

Andrea Garolla\*1, Gabriel Cosmin Petre1<sup>†</sup>, Francesco Francini-Pesenti2<sup>†</sup>, Luca De Toni1,
Amerigo Vitagliano3,4, Andrea Di Nisio1, Carlo Foresta1

<sup>1</sup>Unit of Andrology and Reproductive Medicine & Centre for Male Gamete Cryopreservation, Department of Medicine, University of Padova, Padova, Italy

<sup>2</sup>Department of Medicine, Clinical Nutrition Unit University of Padova, Padova, Italy

<sup>3</sup>Department of Women and Children's Health, University of Padua, Padua, Italy

<sup>4</sup>Unit of Obstetrics and Gynecology, Madonna della Navicella Hospital, Chioggia, Venice, Italy

<sup>\*</sup> Correspondence: andrea.garolla@unipd.it

<sup>&</sup>lt;sup>†</sup>First co-author

Abstract

Background: Dietary supplements (DS) represent a possible approach to improve

sperm parameters and male fertility. A wide range of DS containing different nutrients

is now available. Although many authors demonstrated benefits from some nutrients

in male infertility, their real effectiveness is still under debate. The aim of this study

was to critically review the composition of DS using the Italian market as sample.

Materials & Methods: Active ingredients and their minimal effective daily dose (mFED)

were identified through literature search. Thereafter, we created a formula to classify

the expected efficacy of each DS. Considering active ingredients, their concentration

and the recommended daily dose, DS were scored into three classes of expected

efficacy: higher, lower and none.

Results: Twenty-one DS were identified. Most of them had a large number of

ingredients, frequently at doses below mFED or with unproven efficacy. Zinc was the

most common ingredient of DS (70% of products), followed by selenium, arginine,

coenzyme Q and folic acid. By applying our scoring system, 9.5% of DS fell in higher

class, 71.4% in lower class and 19.1% in the class with no expected efficacy.

Conclusions: DS marketed in Italy for male infertility frequently include effective

ingredients but also a large number of substances at insufficient dose or with no

proven efficacy. Manufacturers and physicians should better consider the scientific

evidence on effective ingredients and their doses before formulating and prescribing

2

these products.

**Keywords:** fertility; male reproduction; semen parameters; supplements; ingredients

### Introduction

Infertility is a pathological condition defined as the inability of a sexually active, non-contracepting couple to achieve pregnancy in one year [1]. Both male and female factors can lead to infertility. In particular, according to the causes, it has been reported that 29.3% is due to male a factor, 37.1% to a female factor, 17.6% to both male and female factors, with the remaining percentage considered as idiopathic [2]. It is estimated that around 10-15% of all couples are affected by infertility, thus representing a global concern in most of developed countries [3].

Among male infertility causes, many recent studies have emphasized the role of genital tract inflammation, incorrect lifestyles and malnutrition [4]. On this regard, weight excess and other conditions such as metabolic syndrome, alcohol abuse, cigarette smoking, exposure to environmental pollutants etc. have been strongly related to worse sperm quality and infertility. A major driving hypothesis is that these conditions, by inducing an elevation of reactive oxygen species (ROS) and nitrogen species (RONS), are able to alter the balance of the redox status of both the steroidogenic cell population and the germ line cell populations, leading to the impairment of the hypothalamic-pituitary-testicular axis and the reduction of sperm quality [5].

A large number of recent studies have focused on the ability of many substances, generally termed as *nutraceuticals*, to improve the hormonal status and sperm parameters by different mechanisms [6]. Nutraceuticals are used as ingredients of dietary supplements (DS), widely marketed for the prevention or treatment of the most disparate pathological conditions. From a legislative point of view, the European Food Safety Agency (EFSA) defines that DS are not intended for the treatment or prevention of disease in humans, but only to support specific physiological function [7]. Currently, DS are widely prescribed to improve physiological aspects related to male fertility.

Many DS are available on the market with various formulations, containing both nutrients and botanicals at different doses. Despite many authors have demonstrated positive effects of some ingredients on semen parameters and fertility outcomes [8], many others also showed the lack of efficacy and even potentially harmful side effects [9]. In a recent position statement, the Italian Society of Andrology and Sexual Medicine (SIAMS) summarized the state of the art on each single ingredient currently used in the andrological field. In this paper authors concluded that there is still limited scientific evidence on the possible role of any nutraceutical in andrology and that the use of antioxidants can be suggested only in patients with idiopathic infertility, after a specific diagnostic workup. However, to date no regulation or guidelines are available for the use of these products, generating confusion for both prescribers and patients [10]. Moreover, several factors make difficult and still empirical to address the right ingredient for the right patient. In particular, it is difficult to identify the correct DS since each product contains different ingredients ad different doses.

The purpose of this study was to evaluate the likely efficacy of the DS typically used for male infertility, estimated on base of the declared composition and on available data on their safety-activity profile, using the Italian market as sample.

# **Materials & Methods**

We collected the names and formulations of the products registered in Italy by referring to the register of the Italian Ministry of Health [11].

A systematic literature review was also performed in order to evaluate, for all the supplements identified, the effectiveness of their ingredients in improving male fertility and their minimum effective dose per day. The literature search was conducted in MEDLINE, Scopus, EMBASE, and Cochrane Library registers until 31/03/2020. The key terms used for the search were: fertility or male reproduction or semen parameters and supplements or ingredients. Only randomized clinical trials (RCT), meta-analyses and reviews were considered eligible. In order to rule out the possible interactions between ingredients, only studies that used active substances alone or in combination with at most other three ingredients were considered. Figure 1 displays the flow diagram of the selection of eligible papers.




Figure 1. Flow diagram of the selection of eligible papers.

To establish the efficacy of each ingredients we considered only dose having at least one RCT or systematic review and metanalysis of RCTs, demonstrating a significant effect on any sperm parameters involved in male fertility. Significance was set at p-value <0.05. Regarding the daily dose of each active ingredient with nutrient characteristics, we referred to the tolerable Upper intake Levels (UL) as reported in Dietary Reference Intake (DRI) [12].

Based on the results of available articles, we were able to identify the minimal effective daily dose (mFED) able to improve male fertility for each active ingredient. Therefore, we classified ingredients and suggested daily dose in each supplement into three categories (A,B,C): reported efficacy with a dose achieving the mFED (A), reported efficacy but with a dose below mFED (B) and unreported data of efficacy (C). To classify DS, we created a formula tacking into consideration the three classes of ingredients and their number:

$$Score = \frac{(2A + B - C)}{2N} \times (A + \frac{B}{2})$$

In particular, the above formula was conceived based on the following sequential steps:

- 1) In particular, each class of ingredients was given an arbitrary value: A = +2, B=+1 and C= -1;
- 2) these values were multiplied for the respective number of ingredients within each supplement (*A*, *B* and *C* respectively), obtaining a total score given by the sum of each category (2A+B-C);
- 3) As the number of ingredients highly differed between supplements, we standardized the above total score by dividing it for the maximum possible score for that supplement, by assuming that each ingredient was of class A (=2N, where N is the total number of ingredients in each supplement);
- 4) In order to correct this value for the number of ingredients of only categories A and B, the relative score was multiplied for the sum of high efficacy ingredients plus half (as a proxy of their lower efficacy) the number of moderate efficacy ingredients (A+B/2), finally obtaining a corrected score for each supplement.

5) Given the distribution of the scores resulted into 3 main clusters, we classified DS into three categories, resembling the efficacy of the ingredients: higher expected efficacy (corrected score ≥4), lower expected efficacy (4< corrected score > 1) and no expected efficacy (corrected score ≤1).

# Results

We evaluated the 21 DS marketed in Italy for male infertility. Within the active ingredients contained in the DS, the literature search allowed us to identify 42 studies (RCTs or metanalyses) reporting their efficacy on sperm parameters (figure 1). By this analysis we found that 18 of these ingredients had a proven efficacy. The complete list of ingredients with clinical evidence of efficacy, the respective references, evaluated sperm parameters and employed daily doses, are summarized in table 1. In the right column, the mFED of each ingredient is reported. In some RCT and meta-analyses, marked with an asterisk, the employed dose exceeded the reported UL. In particular, all the studies involving zinc evaluated the effect of this ingredient at a dose exceeding UL. For each active ingredient, the evidence of efficacy was supported by at least two RCTs or meta-analysis, excluding astaxanthin, D-aspartic acid and L-citrulline, which had only one reference.

Active ingredients	References	Evaluated Sperm Parameters	Employed daily dose	Minimal fertility effective dose (mFED)
	[ <mark>23</mark> ]*	concentration	50 mg	
Zinc	[ <mark>24</mark> ]*	concentration	66 mg	50 mg
	[ <mark>25</mark> ]*	morphology	66 mg	
	[ <mark>23</mark> ]	linear progression	50 μg	
Selenium	[ <mark>26</mark> ]	concentration	100 μg	50 μg
	[ <mark>27</mark> ]	concentration/motility	200 μg	
	[ <mark>28</mark> ]	count	25 μg	
Vitamin B12	[ <mark>29</mark> ]	count	1500 μg	25 μg
	[ <mark>30</mark> ]	count	6000 μg	
	[ <mark>31</mark> ]	count/motility	400 μg	
Folic Acid	[ <mark>32</mark> ]	volume/motility	500 μg	400 μg
	[ <mark>33</mark> ]	DNA damage	500 μg	
I Arginino	[ <mark>34</mark> ]	progressive motility	1,4 g	1.4.~
L-Arginine	[ <mark>35</mark> ]	concentration/motility	1,4 g	1,4 g
L-Citrulline	[ <mark>36</mark> ]	volume/concentration motility/vitality	1,2 g	1,2 g
α-Lipoic Acid	[ <mark>37</mark> ]	concentration/motility	600 mg	600 mg

	[ <mark>38</mark> ]	count/motility	600 mg	
	[ <mark>39</mark> ]	motility/morphology	600 mg	
	[ <mark>40</mark> ]	motility	1 g	
L-Carnitine	[ <mark>41</mark> ]	count/motility	2 g	1 g
(LC/LAC)	[ <mark>42</mark> ]	concentration/motility	2 g	ı g
	[ <mark>43</mark> ]	motility	3 g	
N-Acetyl Cysteine	[ <mark>44</mark> ]	motility/DNA damage	600 mg	
(NAC)	[ <mark>45</mark> ]	motility/DNA damage	600 mg	600 mg
(NAC)	[ <mark>27</mark> ]	motility/morphology	600 mg	
	[ <mark>46</mark> ]	motility	200 mg	
Coenzyme Q10	[ <mark>47</mark> ]	count/motility	200 mg	200 mg
	[ <mark>48</mark> ]	concentration/morphology	300 mg	
Astaxanthin	[ <mark>49</mark> ]	motility	16 mg	16 mg
D-Aspartic Acid (DAA)	[ <mark>50</mark> ]	count/motility	2,7 g	2,7 g
	[ <mark>51</mark> ]	count/motility	250 mg	
Tribulus Terrestris DE	[ <mark>52</mark> ]	morphology/motility	500 mg	250 mg
	[ <mark>53</mark> ]	count/morphology	6000 mg	
Myoinositol	[ <mark>54</mark> ]	motility	2 g	2 g
IVIYOIIIOSILOI	[ <mark>55</mark> ]	concentration	4 g	2 g
	[ <mark>56</mark> ]	motility/DNA damage	20 mg	
or Tocophorol	[ <mark>43</mark> ]	motility/morphology	268.46 mg	20 mg
lpha-Tocopherol	[ <mark>57</mark> ]	motility/lipid oxidation	300 mg	ZU IIIg
	[ <mark>58</mark> ]*	DNA damage	1000 mg	
	[ <mark>59</mark> ]	concentration/motility	0.5 g	
Vitamin C	[ <mark>60</mark> ]	motility	1 g	0.5 g
	[ <mark>58</mark> ]	DNA damage	1 g	
EPA + DHA	[ <mark>61</mark> ]	concentration/motility	0.72 g + 0.48 g	DHA 0 49 a
EPA + DHA	EPA + DHA [62] DNA damage		0.14 g + 1 g	DHA 0,48 g
Lycopono	[ <mark>63</mark> ]	concentration/motility	4 mg	4 mg
Lycopene	[ <mark>64</mark> ]	count/morphology	8 mg	4 IIIg

**Table 1.** Active ingredients with evidence of efficacy, references, evaluated sperm parameters, employed daily doses and minimal fertility effective dose (mFED). \*The employed dose exceeded/reach UL.

**LC**: L-Carnitine; **LAC**: Acetyl L-Carnitine; **EPA**: Eicosapentaenoic acid; **DE**: Dry Extract; **DHA**: docosahexaenoic acid

Ingredients without clinical evidence in the improvement of male fertility (no RCT or metanalysis) are listed in table 2.

Astragalus DE
Damiana DE
Nettle DE
Catuba DE
Ecklonia bicyclis DE
L-Taurine
Glutathione
Glucosamine
SOD
Vitamin D3

Vitamin B1	
Riboflavin	
Niacin	
Vitamin B5	
Vitamin B6	
Biotin	
Manganese	

**Table 2.** Ingredients without clinical evidence of efficacy.

**DE**: Dry Extract; **SOD**: super oxide dismutase.

These ingredients were frequently present in analyzed supplements. A large number of DS contained one or more ineffective ingredients. The composition of the 21 DS and the daily doses of their active ingredients are summarized in table 3.

	DS 1	•••	DS 2 😇		DS 3 🖅		DS 4	DS 4 😟			DS 6 🖭		DS 7 😇	
Active	S = 3,	S = 3,12		S = 2,08		S = 3,66		S = 0,16		,1	S = 2,25		S = 3,37	
ingredients	Daily dose	EV	Daily dose	EV	Daily dose	EV	Daily Dose	EV	Daily dose	EV	Daily Dose	EV	Daily dose	EV
Zinc	7,5 mg	0	10 mg	0	12,5 mg	0	1,5 mg	0			13 mg	0		
Selenium	60 μg	•			83 μg	•					30 μg	0	55 μg	•
Vitamin B12							33 mg	•						
Folic Acid	200 μg	0					400 μg	•			400 μg	•	200 μg	0
L-Arginine	100 mg	0			1000 mg	0			2500 mg	•	125 mg	0	30 mg	0
L-Citrulline														
α-Lipoic Acid							50 mg	0						
L-Carnitine					1000 mg	•					200 mg	0	30 mg	0
N-Acetyl Cysteine (NAC)														
Coenzyme Q10	10 mg	0	200 mg	•	10 mg	0			200 mg	•	7,5 mg	0		
Astaxanthin	15 mg	0		, and the second										

D-Aspartic Acid (DAA)			2660 mg	•									
Tribulus terrestris DE			1116		800 mg	•							,
Myoinositol					mg							1000	•
α-Tocopherol	30 mg	•			12 mg	0		30 mg	•	36 mg	•	mg 30 mg	•
Vitamin C	60 mg	0						180 mg	0				,
DHA													
Lycopene					15 mg	•							
Astragalus DE					300 mg								,
Damiana DE													
Nettle DE													
Catuba DE													
Ecklonia bicyclis DE													
L-Taurine								500 mg					
Glutathione							30 mg			40 mg			
Glucosamine													
SOD							154 UI						
Vitamin D3													
Vitamin B1													
Riboflavin							25 mg						
Niacin							36 mg						
Vitamin B5													
Vitamin B6							9,5 mg						
Biotin													
Manganese													

	DS 8	DS 8 😟		DS 9 🖅		DS 10		DS 11		1 <b>2</b> )	DS 13		DS 14	
Active	S =	1	S = 2,81		S = 2,66		S = 0,5		S = 1,14		S = 4,32		S = 2,5	
ingredient	Dail		Dail		Dail		Dail		Dail		Dail		Dail	
S	y dos	E V	y dos	E V	y dos	E V	y dos	E V	y dos	E V	y dos	E V	y dos	E V
	е		е		е		е		е		е		е	
Zinc			40 mg	0	12,5 mg	0			10 mg	0			15 mg	0
Selenium			60 μg	•					55 μg	•	55 μg	•	83 μg	•
Vitamin B12									2,5 μg	0			5 μg	0
Folic Acid			800 μg	•					400 μg	•	200 μg	0		
L-Arginine	200 mg	0	250 mg	0	100 mg	0					30 mg	0		
L-Citrulline					800 mg	0								

α-Lipoic Acid									300 mg	0			800 mg	•
L-Carnitine	200 mg	0	400 mg	0					500 mg	0	30 mg	0		
N-Acetyl														
Cysteine									300	0	600	•		
(NAC)									mg		mg			
Coenzyme	15		15		100				20				200	_
Q10	mg	0	mg	0	mg	0			mg	0			mg	•
Astaxanthin														
D-Aspartic					80									
Acid (DAA)					mg	0								
Tribulus							300							
terrestris								•						
DE							mg							
Inositol							1000 mg	•	100 mg	0	1000 mg	•	1000 mg	•
α-	30	•	120		30	•					30	•		
Tocopherol	mg		mg		mg						mg	•		
Vitamin C														
DHA														
Lycopene									4 mg	•				
Astragalus DE														
Damiana DE														
Nettle DE														
Catuba DE	50 mg													
Ecklonia							200							
bicyclis DE							mg							
L-Taurine														
Glutathione			80 mg											
Glucosamin			_				150							
е							mg							
SOD														
Vitamin D3														
Vitamin B1									1,1 mg					
Vitamin B2									1,4 mg				2,8 mg	
Vitamin B3									16 mg					
Vitamin B5									6 mg					
Vitamin B6									1,4 mg				2,8 mg	
Biotin									100 μg					
Manganese									2 mg					

DS 15	DS 16	DS 17	DS 18	DS 19	DS 20	DS 21
$\odot$	<u>:</u>	•••	•••	$\odot$	<u>:</u>	<u>:</u>

	S = 4	33	S = 2,	45	S = 2	06	S = 2	06	S =	1	S = 1	05	S =	2
Active	Dail		Dail		Dail		Dail		Dail		Dail		Dail	
ingredient	у	E	y	E	y	E	y	E	y	E	y	E	y	E
S	dose	V	dose	V	dose	V	dose	V	dose	V	dose	V	dose	V
	15		22,5		10		10		6,5		10			
Zinc	mg	0	mg	0	mg	0	mg	0	mg	0	mg	0		
Selenium	50	•			80	•	50				55	•		
	μg				μg	_	μg	_			μg			
Vitamin B12	2,5	0					1,5	0						
·	μg 400		300		200		μg 200						400	
Folic Acid	400 μg	•	μg	0	μg	0	200 μg	0					400 μg	•
	P6		2500		P6		200				30			
L-Arginine			mg	•			mg	0			mg	0		
L-Citrulline	3000	•							200	0				
	mg	•							mg					
α-Lipoic														
Acid	4000		200				400				44.7			<u> </u>
L-Carnitine	1000 mg	•	200 mg	0			400 mg	0			44,7 mg	0		
N-Acetyl	IIIg		IIIg				IIIg				IIIg			
Cysteine														
(NAC)														
Coenzyme	200	•					100	0	90	0				
Q10	mg						mg		mg					
Astaxanthin					16 mg	•	10 mg	0						
D-Aspartic									1000	0				
Acid (DAA)									mg					
Tribulus														
terrestris DE														
Inositol					50 mg	0					500 mg	0	4000 mg	•
α-	40		30				12						8	
Tocopherol	mg	•	mg	•			mg	0						
Vitamin C	80	0					100	0			180	0		
	mg						mg				mg			
DHA					100 mg	0								
Lycopene	10	•												
	mg													
Astragalus DE														
Damiana DE	400													
	mg													
Nettle DE	300 mg													
Catuba DE														
Ecklonia														
bicyclis DE											22-			
L-Taurine											300			
	40						40				mg			
Glutathione	mg						mg							
Glucosamin							Ĭ							
e														ļ
COD					150									
SOD		l	I .	<u>I</u>	mg	l	L	l	I		<u>I</u>	l	I	L


Vitamin D3				3,7				
				5				
				μg				
Vitamin B1								
Vitamin B2								
Vitamin B3								,
Vitamin B5								
Vitamin B6								
Biotin								
Manganese				-				

**Table 3.** List of dietary supplements (**DS**) with graphic representation of their expected efficacy ( higher, lower and no expected efficacy) and relative scores (**S**). For each supplement are indicated active ingredients, daily doses and their efficacy value (**EV**) represented by following symbols: ( or proported efficacy and achievement of mFED; (o) reported efficacy but below mFED; (□) unreported role in male fertility.

**DE**: Dry Extract; **SOD**: super oxide dismutase; **DHA**: docosahexaenoic acid. Moreover, for each supplement, the scores of expected efficacy and the symbols summarizing the efficacy of their ingredients are reported. A detailed analysis of this table raised the following considerations: i) all supplements were mixtures of active ingredients; ii) in each supplement the number of ingredients ranged from 2 up to 17, with a mean number higher than 7; iii) 13 of 21 supplements contained at least 1 ingredient without proven efficacy; iv) 19 supplements had ingredients below mFED; v) indeed, 1 supplement contained even 7 ingredients dosed below mFED; vi) 1 supplement contained only active ingredients satisfying mFED; vii) The product number 9 had a nutrient reaching UL (zinc 40 mg/day); viii) zinc was the most used ingredient, followed by selenium, arginine, coenzyme Q, folic acid and carnitine. These substances were present in more than 50% of DS, whereas all the remaining

The distribution of DS into the 3 classes of efficacy is reported in Figure 2. Two DS out of 21 (9.5 %) were included in the higher expected efficacy group. The most part of remaining products (71.4 %) fell in the lower expected efficacy group, and four (19.1 %) in the group with no efficacy.

ingredients were represented in 10% or less of products.



**Figure 2.** Distribution of supplements in classes of expected efficacy. \*This supplement has a content of Zinc reaching the UL.

## Discussion

This article aimed to evaluate the formulations of supplements for male infertility using the Italian market as sample. In general, there is still poor evidence in terms of large well-designed randomized and placebo-controlled trials availability, supporting the efficacy of nutraceutical products in the area of male reproductive health. Nevertheless, these products are commonly administered to infertile patients [8]. Since a medical prescription is not necessary to purchase dietary supplements, subjects seeking fertility may have an easy access to these products [10]. As a proof of concept, the Italian market of supplements generated 3.3 billion euros in 2019, with an increase of 4.3% compared to 2018 [13].

Whilst a rational use of supplements may be potentially beneficial for infertility, we need to stress that their uncontrolled use is potentially harmful for patients' health due to direct toxic effects and interaction with drugs or nutrients. In this respect, we were surprised to point out that all RCTs and metanalyses on zinc for male infertility relied on doses always exceeding the UL. Over this background, in the near future it would be desirable to better define thoughtful criteria for each supplement in use.

Our analysis found that beside the gap of literature, the market of food supplements is still supported by poor scientific evidence. The majority of DS contained a huge number of ingredients, up to 17. The mixture of such a high number of ingredients may generate different issues, including a low concentration of each substance (i.e. necessitating of two or more administrations to reach the daily effective dose), a large volume of pills and high risk of interactions. What is more, we found that some ingredients included in many DS had no scientific evidence of efficacy (egs. astragalus, vitamin D3, taurine and riboflavin). The formulation of pills with a large number of ingredients, some of which with uncertain benefits, denotes a gap of knowledge of potential biologic targets by manufacturers. Moreover, it has been reported that some plant extracts, present in many of these supplements, are likely to interact with drug metabolism [14,15]. This aspect raises further concerns on the safety of these products.

Very frequently, nutrients were present in DS at a dosage below mFED. This situation was more common among products with high number of ingredients. The administration of any active substance with dose below mFED appears as scientifically unjustified due to uncertainties in the therapeutic results. Differently, when the number of ingredients was small, the dose often satisfied mFED. Another major aspect in the evaluation of supplements concerns safety. Some ingredients, particularly when administrated in high doses, are not free from risks wen used as dietary supplements. For example, folates can mask the B12 deficiency favoring the progression of neurological damage [16]. The combination of these two vitamins could have a synergic effect in improving homocysteine metabolism hence the sperm quality. Noteworthy that vitamin B12, when present, was rarely associated to folic acid [17,18]. Furthermore, zinc reduces the copper intestinal absorption interfering with its carrier [19]. In respect to this, we want to stress that one supplement on the market contained a dose of zinc reaching the UL.

On a positive note, our analysis revealed that some active ingredients with proven efficacy are frequently present in analyzed supplements. Previous studies demonstrated that some ingredients are particularly effective in specific patients' conditions. Substances with antioxidant properties are indicated in male accessory glands inflammation, both related to microbial and non-microbial origin. Several

studies performed in asthenozoospermic infertile patients, showed that the positive effect of selenium supplementation is dependent on the correct structure of mitochondrial capsule [20]. Carnitine supplementation induced a significant increase of sperm motility in cases of asthenozoospermia with preserved mitochondrial function [21]. Due to the key role of zinc in the processes of DNA compaction, administration of this micronutrient was successful in improving sperm morphology and DNA integrity in patients with prostate abnormalities [22].

Based on active ingredients reaching mFED we created a grading scale of supplements distinguishing three classes of expected efficacy. Three products were present in the higher class, some of which contained ineffective or underdosed ingredients. Most of the supplements fell in the lower group of expected efficacy. In this class, also a large number of ineffective or underdosed products was present. For an adequate evaluation of these classes, we considered the number of the effective ingredients as the most important criterion of efficacy. A relevant aspect was the use of ineffective or underdosed ingredients that should be absent or less than possible. Another parameter to evaluate a product was the presence a lower number of ingredients.

We acknowledge the application of a non-validated statistical method to calculate scores for each DS may represent a point of weakness of this study. However, as a point of strength, our scoring system relied on high quality evidence coming from RCTs or systematic review and meta-analyses of RCTs, which represents a reliable approach to critically weight the expected efficacy of dietary supplements. The same approach could be applied to evaluate products used in other clinically conditions.

In conclusion, this study showed that most DS on the Italian market contain ingredients with proven efficacy in male infertility. Nevertheless, a non-negligible number of DS are mixtures of substances with uncertain or unproven benefits, whose administration may be unhelpful or even harmful for infertile patients. On that basis, we believe manufacturers should carefully scrutiny scientific evidence before delivering each supplements' formulation. Accordingly, physicians should evaluate the composition of DS and the dose of each single constituent before considering their clinical use. Finally, the choice for DS should be tailored on to the specific patient's fertility problem.

**Author Contributions:** AG and GCP contributed to the conception/design of the research and acquisition/analysis of the literature data; AG, GCP and FFP equally contributed drafted the manuscript; ADN concept and performed data analyses; LDT, AV and CF critically revised the paper for important intellectual content. All authors revised and approved the final manuscript, agree to be fully accountable for ensuring the integrity and accuracy of the work. All authors had full access to all the data in the study and can take responsibility for the integrity of them and the accuracy of the analysis.

**Conflicts of Interest:** All authors declare no competing interests.

# References

- World Health Organization. Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. *Lancet.* 1990, 336, 955-959.
- 2. <a href="http://old.iss.it/binary/rpma/cont/7">http://old.iss.it/binary/rpma/cont/7</a> 2017 Report.pdf (accessed on 20/03/2020).
- 3. Winters BR, Walsh T. The epidemiology of male infertility. *Urologic Clinics of North America*. **2014**, *41*, 195-204.
- 4. Lotti F, Maggi M. Ultrasound of the male genital tract in relation to male reproductive health. *Hum Reprod Update*. **2015**, *21*, 56-83.
- 5. Ferlin A, Foresta C. New genetic markers for male infertility. *Curr Opin Obstet Gynecol*. 2**015**, *26*, 193-98.
- 6. Falsig A.L, Gleerup C.S, Knudsen UB. The influence of omega-3 fatty acids on semen quality markers: a systematic PRISMA review. *Andrology*. **2019**, *22*, 2047-2919.
- 7. http://data.europa.eu/eli/reg/2006/1924/2012-11-29 (accessed on 20/03/2020).

- 8. Cui T, Kovell R.C, Brooks D.C, Terlecki R.P. A urologist's guide to ingredients found in top-selling nutraceuticals for men's sexual health. *J Sex Med.* **2015**, *12*, 2105-2117.
- 9. Henkel R, Sandhu I.S, Agarwal A. The excessive use of antioxidant therapy: A possible cause of male inferility?. *Andrologia*. **2019**, *51*, 0303-4569.
- 10. Calogero A.E, Aversa A, La Vignera S, Corona G, Ferlin A. The use of nutraceuticals in male sexual and reproductive disturbances: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS). *J Endocrinol Invest.* 2017, 40, 1389-1397.
- 11. <a href="http://www.salute.gov.it/portale/temi/documenti/integratori/registro">http://www.salute.gov.it/portale/temi/documenti/integratori/registro</a> integratori per prodotto.pdf (accessed on 20/03/2020).
- 12. Dietary Reference Intakes ISBN: 978-0-309-15742-1 DOI: https://doi.org/10.17226/11537
- 13. <a href="https://www.federsalus.it/il-mercato-degli-integratori-dinamiche-aggiornate-a-marzo-2019/">https://www.federsalus.it/il-mercato-degli-integratori-dinamiche-aggiornate-a-marzo-2019/</a> (accessed on 20/03/2020).
- 14. Szewczyk K, Zidorn C. Ethnobotany, phytochemistry, and bioactivity of the genus Turnera (Passifloraceae) with a focus on damiana--Turnera diffusa. *J Ethnopharmacol.* **2014**, *152*, 424-43.
- 15. Jung H.A, Roy A, Jung J.H, Choi J.S. Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B. *Arch Pharm Res.* **2017**, *40*, 480-491.
- 16. Naderi N, House J.D. Recent Developments in Folate Nutrition. *Adv Food Nutr Res.* **2018**, *83*, 195-213.
- 17. Najafipour R, Moghbelinejad S, Aleyasin A, Jalilvand A. Effect of B9 and B12 vitamin intake on semen parameters and fertility of men with MTHFR polymorphisms. *Andrology*. **2017**, *5*, 704-710.
- 18. Qi Y.N, Ma J, Han R.Y, Liu W.J, Wang S.S. Correlation of the levels of seminal plasma homocysteine, folate and cobalamin with semen parameters in obese men. *Zhonghua Nan Ke Xue*. **2018**, *24*, 883-886.
- 19. Duncan A, Yacoubian C, Watson N, Morrison I. The risk of copper deficiency in patients prescribed zinc supplements. *J Clin Pathol.* **2015**, *68*,723-5.

- 20. Foresta C, Flohé L, Garolla A, Roveri A, Ursini F, Maiorino M. Male fertility is linked to the selenoprotein phospholipid hydroperoxide glutathione peroxidase. *Biol Reprod.* **2002**, *67*, 967-71.
- 21. Garolla A, Maiorino M, Roverato A, Roveri A, Ursini F, Foresta C. Oral carnitine supplementation increases sperm motility in asthenozoospermic men with normal sperm phospholipid hydroperoxide glutathione peroxidase levels. *Fertil Steril.* **2005**, *83*, 355-61.
- 22. Foresta C, Garolla A, Cosci I, Menegazzo M, Ferigo M, Gandin V, De Toni L. Role of zinc trafficking in male fertility: from germ to sperm. *Hum Reprod.* **2014**, *29*, 1134-45.
- 23. Majzoub A, Agarwal A. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia. *Indian J Urol.* **2017**, *33*, 207-214.
- 24. Ebisch I.M, Pierik F.H, DE Jong F.H, Thomas C.M, Steegers-Theunissen R.P. Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men? *Int J Androl.* **2006**, *29*, 339-45.
- 25. Azizollahi G, Azizollahi S, Babaei H, Kianinejad M, Baneshi M.R, Nematollahimahani S.N. Effects of supplement therapy on sperm parameters, protamine content and acrosomal integrity of varicocelectomized subjects. *Journal of Assisted Reproduction and Genetics.* **2013**, *30*, 593-9.
- 26. Smits R.M, Mackenzie-Proctor R, Yazdani A, Stankiewicz M.T, Jordan V, Showell M.G. Antioxidants for male subfertility. *Cochrane Database Syst Rev.* **2019**, *3*, CD007411.
- 27. Safarinejad M.R, Safarinejad S. Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. *J Urol.* **2009**, *181*, 741-51.
- 28. Banihani S.A. Vitamin B12 and Semen Quality. Biomolecules. 2017, 9,7.
- 29. Kumamoto Y., Maruta H., Ishigami J., Kamidono S., Orikasa S., Kimura M., Yamanaka H., Kurihara H., Koiso K., Okada K., et al. Clinical efficacy of mecobalamin in the treatment of oligozoospermia—Results of double-blind comparative clinical study. *Hinyokika Kiyo*. **1988**, *34*, 1109-1132.
- 30. Moriyama H, Nakamura K, Sanda N, Fujiwara E, Seko S, Yamazaki A, Mizutani M, Sagami K, Kitano T. Studies on the usefulness of a long-term, high-dose

- treatment of methylcobalamin in patients with oligozoospermia. *Hinyokika Kiyo*. **1987**, *33*, 151-6.
- 31. Calogero A.E, Gullo G, La Vignera S, Condorelli RA, Vaiarelli A. Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebocontrolled study. *Andrology*. **2015**, *3*, 491-5.
- 32. Wong W.W.Y, Merkus H.H.M.W, Thomas C.M, Menkveld R, Zielhuis G.A, Steegers-Theunissen R.P. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. *Fertil Steril*. **2002**, *77*, 491-8.
- 33. Showell M.G, Brown J, Yazdani A, Stankiewicz M.T, Hart R.J. Antioxidants for male subfertility. *Cochrane Database Syst Rev.* **2011**, *19*, CD007411.
- 34. Stanislavov R, Nikolova V, Rohdewald P. Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. *Phytother Res.* **2009**, 23, 297-302.
- 35. Nikolova V, Stanislavov R, Vatev I, Nalbanski B, Pŭnevska M. Sperm parameters in male idiopathic infertility after treatment with prelox. *Akush Ginekol (Sofiia)*. **2007**, *46*, 7-12.
- 36. Stanislavov R, Rohdewald P. Sperm quality in men is improved by supplementation with a combination of L-arginine, L-citrullin, roburins and Pycnogenol®. *Minerva Urol Nefrol.* **2014**, *66*, 217-23.
- 37. Haghighian H.K, Haidari F, Mohammadi-Asl J, Dadfar M. Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. *Fertil Steril.* **2015**, *104*, 318-24.
- 38. Salas-Huetos A, Bulló M, Salas-Salvadó J. Dietary patterns, foods and nutrients in male fertility parameters and fecundability: a systematic review of observational studies. *Human Reproduction Update*. **2017**, *23*, 371-89.
- 39. Dong L, Zhang X, Yang F, Li J, Yu X, Li Y. Effect of oral alpha-lipoic acid (ALA) on the treatment of male infertility: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. **2019**, *98*, 18453.

- 40. Mehni M.N, Ketabchi A.A, Hosseini E. Combination effect of Pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. *Iran J Reprod Med.* **2014**, *12*, 817-24.
- 41. Peivandi S, Abasali K, Narges M. Effects of L-carnitine on infertile men's spermogram; a randomised clinical trial. *Journal of Reproduction and Infertility*. **2010**, *10*, 331.
- 42. Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L, Dondero F, Gandini L.

  Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. *Fertil Steril.* **2003**, *79*, 292-300.
- 43. Ahmadi S, Bashiri R, Ghadiri-Anari A, Nadjarzadeh A. Antioxidant supplements and semen parameters: An evidence based review. *Int J Reprod Biomed (Yazd)*. **2016**, *14*, 729-736.
- 44. Walczak-Jedrzejowska R, Wolski J.K, Slowikowska-Hilczer J. The role of oxidative stress and antioxidants in male fertility. *Cent Eur J Uro.* **2013**, *66*, 60-67.
- 45. Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. *Urology*. **2009**, *74*, 73-6.
- 46. Nadjarzadeh A, Sadeghi M.R, Amirjannati N, Vafa MR, Motevalian S.A, Gohari M.R, Akhondi M.A, Yavari P, Shidfar F. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. *J Endocrinol Invest.* 2011, 34, 224-228.
- 47. Safarinejad M.R, Safarinejad S.S, Shafiei N, Safarinejad S.S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. *J Urol.* **2012**, *188*, 526-31.
- 48. Safarinejad M.R. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. *J Urol.* **2009**, *182*, 237-48.
- 49. Comhaire F.H, El Garem Y, Mahmoud A, Eertmans F, Schoonjans F. Combined conventional/antioxidant "Astaxanthin" treatment for male infertility: a double blind, randomized trial. *Asian J Androl.* **2005**, *7*, 257-62.

- 50. D'Aniello G, Ronsini S, T Notari T, Grieco N, Infante V, D'Angelo N, Mascia F, Di Fiore M.M, Fisher G, D'Aniello A. D-Aspartate, a Key Element for the Improvement of Sperm Quality. *Advances in Sexual Medicine*. **2012**, *2*, 47-53.
- 51. Ismail S.B, Bakar M.B, Nik Hussain N.H, Norhayati M.N, Sulaiman S.A, Jaafar H, Draman S, Ramli R, Wan Yusoff W.Z. Comparison on the effects and safety of tualang honey and tribestaan in sperm parameters, erectile function and hormonal profile among oligospermia males. *Evid Based Complimen Altern Med.* 2014, 2014, 126138.
- 52. Setiawan L, Tribulus terrestris L. extract improves spermatozoa motility and increases the efficiency of acrosome reaction in subjects diagnosed with oligoastheno-teratozoospermia. *Adv Male Reprod Physiol.* **1996**, *2*, 105-114.
- 53. Sanagoo S, Oskouei B.S, Abdollahi N.G, Salehi-Pourmehr H, Hazhir N, Farshbaf-Khalili A. Effect of *Tribulus terrestris* L. on sperm parameters in men with idiopathic infertility: A systematic review. *Complement Ther Med.* **2019**, *42*, 95-103.
- 54. Vazquez-Levin M.H, Verón G.L. Myo-inositol in health and disease: its impact on semen parameters and male fertility. *Andrology*. **2020**, *8*, 277-298.
- 55. Condorelli R.A, La Vignera S, Mongioì L.M, Vitale S.G, Laganà A.S, Cimino L, Calogero A.E. Myo-inositol as a male fertility molecule: speed them up!. *Eur Rev Med Pharmacol Sci.* **2017**, *21*, 30-35.
- 56. Omu A.E, Al-Azemi M.K, Kehinde E.O, Anim J.T, Oriowo M.A, Mathew T.C. Indications of the mechanisms involved in improved sperm parameters by zinc therapy. *Med Princ Pract.* **2008**, *17*, 108-16.
- 57. Suleiman S, Eamin Ali M, Zaki Z, El-Malik E, Nasr M. Lipid peroxidation and human sperm motility: protective role of vitamin E. *J Androl.* **1996**, *17*, 530-7.
- 58. Greco E, Iacobelli M, Rienzi L, Ubaldi F, Ferrero S, Tesarik J. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. **J Androl**. *2005*, *26*, 349-53.
- 59. Cyrus A, Kabir A, Goodarzi D, Moghimi M. The effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double blind placebo controlled clinical trial. *International Brazilian Journal of Urology*. **2015**, *41*, 230-8.

- 60. Dawson E.B, Harris W.A, Powell L.C. Relationship between ascorbic acid and male fertility. *World Review of Nutrition and Dietetics*. **1990**, *62*, 1-26.
- 61. Safarinejad MR. Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomized study. *Andrologia*. **2011**, *43*,38-47.
- 62. Martinez-Soto J.C, Domingo J.C, Cardobilla L.P, Pellicer A, Landeras J. Effect of dietary DHA supplementation on sperm DNA integrity. *Fertility and Sterility*. 2010, 94, S235-6.
- 63. Gupta N.P. Lycopene therapy in idiopathic male infertility--a preliminary report. *Int Urol Nephrol.* **2002**, *34*, 369-72.
  - Durairajanayagam D, Agarwal A, Ong C, Prashast P. Lycopene and male infertility. *Asian J Androl.* **2014**, *16*, 420-5.